Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Tran, Pierre V.
Tollefson, Gary D.
Sanger, Todd M.
Lu, Yili
Berg, Paul H.
and
Beasley, Charles M.
1999.
Olanzapine versus haloperidol in the treatment of schizoaffective disorder.
British Journal of Psychiatry,
Vol. 174,
Issue. 1,
p.
15.
Kane, John
1999.
Olanzapine in the long-term treatment of schizophrenia.
British Journal of Psychiatry,
Vol. 174,
Issue. S37,
p.
26.
Green, Ben
1999.
Focus on Olanzapine.
Current Medical Research and Opinion,
Vol. 15,
Issue. 2,
p.
79.
Stephenson, C. M. E.
and
Pilowsky, L. S.
1999.
Psychopharmacology of olanzapine.
British Journal of Psychiatry,
Vol. 174,
Issue. S38,
p.
52.
Fleischhacker, W. Wolfgang
1999.
Invited comment.
Acta Psychiatrica Scandinavica,
Vol. 100,
Issue. 4,
p.
314.
Fleischhacker, W. Wolfgang
1999.
The psychopharmacology of schizophrenia.
Current Opinion in Psychiatry,
Vol. 12,
Issue. 1,
p.
53.
Massie, Jennifer
and
Lewis, Shôn
1999.
Duration of treatment in schizophrenia.
The Journal of Forensic Psychiatry,
Vol. 10,
Issue. 3,
p.
491.
Tollefson, Gary D.
and
Taylor, Cindy C.
2000.
Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent.
CNS Drug Reviews,
Vol. 6,
Issue. 4,
p.
303.
Lund, Brian C
and
Perry, Paul J
2000.
Olanzapine: an atypical antipsychotic for schizophrenia.
Expert Opinion on Pharmacotherapy,
Vol. 1,
Issue. 2,
p.
305.
Dose, M.
2000.
Langzeittherapie der Schizophrenie.
p.
37.
Meltzer, Herbert Y.
2000.
Atypical Antipsychotics.
p.
191.
Möller, Hans-Jürgen
2000.
Definition, Psychopharmacological Basis and Clinical Evaluation of Novel/Atypical Neuroleptics: Methodological Issues and Clinical Consequences.
The World Journal of Biological Psychiatry,
Vol. 1,
Issue. 2,
p.
75.
Sacristán, José A.
Gómez, Juan-Carlos
Montejo, Angel-Luis
Vieta, Eduardo
and
Gregor, Karl J.
2000.
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study.
Clinical Therapeutics,
Vol. 22,
Issue. 5,
p.
583.
Revicki, Dennis A
2000.
The new atypical antipsychotics: a review of pharmacoeconomic studies.
Expert Opinion on Pharmacotherapy,
Vol. 1,
Issue. 2,
p.
249.
Marder, Stephen R.
2000.
Newer antipsychotics.
Current Opinion in Psychiatry,
Vol. 13,
Issue. 1,
p.
11.
Fleischhacker, W. W.
2000.
Psychiatrie der Gegenwart 5.
p.
209.
Duggan, L
Fenton, M
Dardennes, RM
El-Dosoky, A
and
Indran, S
2000.
Cochrane Database of Systematic Reviews.
Kasper, S.
Jones, M.
and
Duchesne, I.
2001.
Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study.
International Clinical Psychopharmacology,
Vol. 16,
Issue. 4,
p.
189.
Bosveld‐van Haandel, L. J. M.
Slooff, C. J.
and
Van Den Bosch, R. J.
2001.
Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.
Acta Psychiatrica Scandinavica,
Vol. 103,
Issue. 5,
p.
335.
Weigmann, Harald
Gerek, Sevda
Zeisig, Alexander
Müller, Matthias
Härtter, Sebastian
and
Hiemke, Christoph
2001.
Fluvoxamine But Not Sertraline Inhibits the Metabolism of Olanzapine: Evidence From A Therapeutic Drug Monitoring Service.
Therapeutic Drug Monitoring,
Vol. 23,
Issue. 4,
p.
410.
eLetters
No eLetters have been published for this article.